Cimduo FDA Approval History
FDA Approved: Yes (First approved February 28, 2018)
Brand name: Cimduo
Generic name: lamivudine and tenofovir disoproxil fumarate
Dosage form: Tablets
Company: Mylan Pharmaceuticals Inc.
Treatment for: HIV Infection
Cimduo (lamivudine and tenofovir disoproxil fumarate) is a combination of two nucleo(t)side reverse transcriptase inhibitors indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.
Development timeline for Cimduo
| Date | Article |
|---|---|
| Mar 2, 2018 | Approval Mylan to Introduce Cimduo (lamivudine and tenofovir disoproxil fumarate) as a New Cost-Saving HIV Combination Treatment in the U.S. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
